AUTHOR INFORMATION

Section 1 of 11

Authored by Sandy Craig, MD, Associate Program Director, Adjunct Assistant Professor, Department of Emergency Medicine, University of North Carolina at Chapel Hill, Carolinas Medical Center

Sandy Craig, MD, is a member of the following medical societies: Alpha Omega Alpha, and Society for Academic Emergency Medicine

Edited by Lance W Kreplick, MD, MMM, Medical Director, Department of Emergency Medicine, Regional Medical Center - Bayonet Point; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Tom Scaletta, MD, Assistant Professor, Department of Emergency Medicine, Rush Medical College; John Halamka, MD, Chief Information Officer, CareGroup Healthcare System, Assistant Professor of Medicine, Department of Emergency Medicine, Beth Israel Deaconess Medical Center; Assistant Professor of Medicine, Harvard Medical School; and Rick Kulkarni, MD, Medical Director, Assistant Professor of Surgery, Section of Emergency Medicine, Yale-New Haven Hospital

Author's Email:	Sandy Craig, MD
Editor's Email:	Lance W Kreplick, MD, MMM

eMedicine Journal, November 30 2006, VOLUME 7, Number 11

INTRODUCTION

Section 2 of 11

Background: Rhabdomyolysis was first described in the victims of crush injury during the 1940-1941 London, England, bombing raids of World War II. It has many etiologies.

Pathophysiology: Rhabdomyolysis is the breakdown of muscle fibers with leakage of potentially toxic cellular contents into the systemic circulation. The final common pathway of rhabdomyolysis may be a disturbance in myocyte calcium homeostasis.

Clinical sequelae of rhabdomyolysis include the following:

• Hypovolemia (sequestration of plasma water within injured myocytes)

• Hyperkalemia (release of cellular potassium into the systemic circulation)

• Metabolic acidosis (release of cellular phosphate and sulfate)

• Acute renal failure (nephrotoxic effects of liberated myocyte components)

• Disseminated intravascular coagulation (DIC)

Frequency:

• In the US: Rhabdomyolysis accounts for an estimated 8-15% of cases of acute renal failure.

Mortality/Morbidity: The overall mortality rate for patients with rhabdomyolysis is approximately 5%; however, the mortality rate of any single patient is dependent upon the underlying etiology and any existing comorbidities.

Sex: Incidence is higher in males than in females, especially in the subgroups of trauma and inherited enzyme deficiencies.

Age: Rhabdomyolysis may occur in infants, toddlers, and adolescents who have inherited enzyme deficiencies of carbohydrate or lipid metabolism or who have inherited myopathies, such as Duchenne muscular dystrophy and malignant hyperthermia.

CLINICAL

Section 3 of 11

History: The clinical presentation is often subtle, underscoring the need for a high index of suspicion.

• In a 1982 study of 87 episodes of rhabdomyolysis in adults, Gabow found that only 50% of patients initially complained of muscle pain. A minority of patients reported dark discoloration of the urine.

• In Gabow's series, 97% of patients reported at least 1 risk factor for rhabdomyolysis. Fifty-nine percent reported multiple risk factors.

• Common risk factors included alcohol abuse (67%), recent soft tissue compression (39%), and seizure activity (24%).

• Other causative factors included trauma (17%), drug abuse (15%), metabolic derangements (8%), hypothermia (4%), flulike illness (3%), sepsis (2%), and gangrene (1%).

• Ward's 1988 review of 157 patients found the following predisposing factors:

• Trauma (38%)

• Ischemia (14%)

• Polymyositis (8%)

• Drug overdose (7%)

• Exertion (6%)

• Seizures (5%)

• Burns (5%)

• Sepsis (3%)

• Hereditary disorders (3%)

• Viral illness (1%)

• In a review of 191 pediatric patients with rhabdomyolysis, Mannix et al studied presenting symptoms, causative factors, and incidence of acute renal failure. The average age was 11 years.

• The most common documented symptoms were muscle pain (45%), fever (40%), and symptoms of viral infection (39%).

• The most common causes of rhabdomyolysis in this pediatric population were viral myositis (38%), trauma (26%), and connective tissue disease (5%). CK levels greater than 6000 IU/L were more likely to be associated with undiagnosed dermatomyositis or hereditary muscle disease than levels less than 6000 IU/L.

• Acute renal failure occurred in 4.7% of patients, all of whom had urinary heme dipstick results of at least 2+.

Physical:

• Focal or diffuse skeletal muscle swelling is rare. In Gabow's series, only 5% of the patients presented with muscle edema.

• Tense and tender muscle compartments suggest compartment syndrome; peripheral pulses that are within reference range do not rule out compartment syndrome because loss of distal pulses is a very late sign.

Causes: The etiologies may be subdivided into traumatic, exercise induced, toxicologic, environmental, metabolic, infectious, immunologic, and inherited classifications.

• Rhabdomyolysis may occur after traumatic events, including the following:

• Significant blunt trauma

• High-voltage electrical injury

• Extensive burns

• Near drowning

• Prolonged immobilization (eg, after excess alcohol or drug consumption, after an unwitnessed incapacitating stroke, following prolonged surgical procedures)

• Rhabdomyolysis may occur after excessive muscular activity, such as the following:

• Sporadic strenuous exercise (eg, marathons)

• Status epilepticus

• Status asthmaticus

• Severe dystonia

• Acute psychosis

• Toxin-mediated rhabdomyolysis may result from substance abuse, including abuse of the following:

• Ethanol

• Methanol

• Ethylene glycol

• Isopropanol

• Heroin

• Methadone

• Barbiturates

• Cocaine

• Amphetamine

• Phencyclidine

• 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)

• Lysergic acid diethylamide (LSD)

• Toxic-mediated rhabdomyolysis may result from prescription and nonprescription medications, including the following:
  • Antihistamines

  • Salicylates

  • Caffeine

  • Fibric acid derivatives (eg, bezafibrate, clofibrate, fenofibrate, gemfibrozil)

  • Neuroleptics

  • Anesthetic and paralytic agents (the malignant hyperthermia syndrome)

  • Amphotericin B

  • Quinine

  • Corticosteroids

  • Atorvastatin

  • Fluvastatin

  • Lovastatin

  • Pitavastatin (marketed in Japan, South Korea, India)

  • Pravastatin

  • Rosuvastatin

  • Simvastatin

  • Cerivastatin (recalled from US market)

  • Theophylline

  • Cyclic antidepressants

  • Selective serotonin reuptake inhibitors (the serotonin syndrome)

  • Aminocaproic acid

  • Phenylpropanolamine (recalled from US market)

  • Propofol (Continuous infusion has caused rhabdomyolysis in children.)

• Rhabdomyolysis may be caused by other toxins, including the following:
  • Carbon monoxide

  • Toluene

  • Hemlock herbs from quail (Rhabdomyolysis after the consumption of quail is well known in the Mediterranean region; it occurs as the result of intoxication by hemlock herbs that the quails consume.)

  • Snake, spider (eg, black widow spider), and massive bee envenomations

• Environmental causes of rhabdomyolysis include the following:
  • Hyperthermia

  • Hypothermia

• Metabolic causes of rhabdomyolysis include the following:
  • Hyponatremia or hypernatremia

  • Hypokalemia

  • Hypophosphatemia

  • Hypothyroidism or hyperthyroidism

  • Diabetic ketoacidosis

  • Nonketotic hyperosmolar diabetic coma

• Viral infectious disease agents may cause rhabdomyolysis, including the following:
  • Influenza types A and B (most common)

  • HIV

  • Coxsackievirus

  • Ebstein-Barr virus

  • Echovirus

  • Cytomegalovirus

  • Adenovirus

  • Herpes simplex virus

  • Parainfluenza virus

  • Varicella-zoster virus

• Bacterial infectious agents may cause rhabdomyolysis, including the following:
  • Francisella tularensis

  • Streptococcus pneumoniae

  • Group B streptococci

  • Streptococcus pyogenes

  • Staphylococcus epidermidis

  • Escherichia coli

  • Borrelia burgdorferi

  • Clostridium perfringens

  • Clostridium tetani

  • Viridans streptococci

  • Plasmodium species

  • Rickettsia species

  • Salmonella species

  • Listeria species

  • Legionella species

  • Mycoplasma species

  • Vibrio species

  • Brucella species

  • Bacillus species

  • Leptospira species

• Fungal infectious agents may cause rhabdomyolysis, including the following:
  • Candida species

  • Aspergillus species

• Causative connective tissue diseases that can cause rhabdomyolysis include the following:
  • Polymyositis

  • Dermatomyositis

• Inherited disorders may cause rhabdomyolysis, including the following:
  • Enzyme deficiencies of carbohydrate or lipid metabolism

  • Myopathies

• Rhabdomyolysis also has been reported in patients with sickle cell anemia and has mistakenly been identified as a pain crisis.

DIFFERENTIALS

Section 4 of 11

Anemia, Sickle Cell
Burns, Thermal
Compartment Syndrome, Extremity
Diabetic Ketoacidosis
Disseminated Intravascular Coagulation
Electrical Injuries
HIV Infection and AIDS
Heat Exhaustion and Heatstroke
Hypernatremia
Hyperosmolar Hyperglycemic Nonketotic Coma
Hypokalemia
Hyponatremia
Hypophosphatemia
Hypothermia
Hypothyroidism and Myxedema Coma
Myopathies
Neuroleptic Malignant Syndrome
Pediatrics, Inborn Errors of Metabolism
Plant Poisoning, Hemlock
Polymyositis
Renal Failure, Acute
Snake Envenomations, Rattle
Spider Envenomations, Widow
Toxicity, Alcohols
Toxicity, Amphetamine
Toxicity, Barbiturate
Toxicity, Carbon Monoxide
Toxicity, Cocaine
Toxicity, Cyclic Antidepressants
Toxicity, Ethylene Glycol
Toxicity, Hallucinogen
Toxicity, MDMA
Toxicity, Medication-Induced Dystonic Reactions
Toxicity, Methamphetamine
Toxicity, Neuroleptic Agents
Toxicity, Phencyclidine
Toxicity, Salicylate
Toxicity, Theophylline
Toxicity, Toluene

Other Problems to be Considered:

Serotonin syndrome

WORKUP

Section 5 of 11

Lab Studies:

• Preliminary diagnosis of rhabdomyolysis requires a high index of suspicion. Definitive diagnosis is made by laboratory evaluation.

• The most useful measurement is for serum creatine kinase (CK). This assay is widely available and 100% sensitive. Rhabdomyolysis has been variously defined as total CK levels 5-10 times above normal in a patient with typical symptoms and/or risk factors.

• Total CK elevation is a sensitive but nonspecific marker for rhabdomyolysis. Suspect early rhabdomyolysis in patients with serum CK levels in excess of 2-3 times the reference range and risk factors for rhabdomyolysis; initiate a full laboratory workup. Remember that the total CK may increase from the initial values, and repeat total CK levels should be drawn every 6-12 hours until a peak level is established.

• Patients with other disorders, such as acute myocardial infarction and acute stroke, may have high CK levels. CK levels have a wide range of distribution among patients with rhabdomyolysis (several hundred to hundreds of thousands of units per liter).

• Serum CK levels peak within 24 hours and should decrease by approximately 30-40% per day after the initial insult. Persistent elevation suggests continuing muscle injury or development of a compartment syndrome.

• A urine dipstick test for blood has positive results in the presence of hemoglobin or myoglobin.

• A urine dipstick test for blood that has positive findings in the absence of red blood cells suggests myoglobinuria.

• Myoglobinuria may be sporadic or resolve early in the course of rhabdomyolysis.

• Urine dipstick findings are positive in only 50% of patients with rhabdomyolysis; therefore, a normal urine dipstick test result does not rule out this condition.

• Aldolase, lactate dehydrogenase (LDH), and serum glutamic-oxaloacetic transaminase (SGOT) are nonspecific enzyme markers that are elevated in patients with rhabdomyolysis.

• Hyperkalemia, an immediate threat to life in the hours immediately after injury, occurs in 10-40% of cases.

• Liberated potassium can cause life-threatening dysrhythmias and death.

• Measure and closely monitor serum potassium levels.

• Acute renal failure develops in 30-40% of patients and is the most serious complication in the days after initial presentation.

• Measure and closely monitor blood urea nitrogen (BUN) and creatinine levels.

• The BUN-creatinine ratio can be decreased because of the conversion of liberated muscle creatine to creatinine.

• Hyperphosphatemia does not require specific therapy.

• Hypocalcemia occurs early in the course of rhabdomyolysis. Supplemental calcium is not recommended.

• Increased purine metabolism causes hyperuricemia. Specific therapy with uricosuric agents or allopurinol is not indicated.

• Obtain the prothrombin time, activated partial thromboplastin time, and platelet count in all patients with rhabdomyolysis. Thromboplastin released from injured myocytes can cause DIC.

Imaging Studies:

• Imaging studies generally play no role in the initial diagnosis of rhabdomyolysis.

• Magnetic resonance imaging (MRI) may be useful in distinguishing various etiologies of rhabdomyolysis.

• One study suggests that bacterial myositis, focal myositis, and idiopathic rhabdomyolysis show a characteristic gadolinium enhancement on MRI (Beese, 1996). Abscesses were found only in bacterial myositis.

• Polymyositis and dermatomyositis have a characteristic uniform distribution pattern with emphasis on the quadriceps muscles.

Other Tests:

• Obtain an electrocardiogram (ECG) early in the course of ED evaluation.

• ECG may reveal changes of acute hyperkalemia, including peaked T waves, prolongation of the PR and QRS intervals, and loss of the P wave or the sine wave.

Procedures:

• Measure the compartment pressures in any patient with severe focal muscle tenderness and a firm muscle compartment.

• Perform a fasciotomy if compartment pressures are sustained in excess of 25-30 mm Hg.

TREATMENT

Section 6 of 11

Prehospital Care: Vigorous hydration with isotonic crystalloid is the cornerstone of therapy for rhabdomyolysis. Retrospective studies of patients with severe crush injuries resulting in rhabdomyolysis suggest that the prognosis is better when prehospital personnel provide fluid resuscitation. Support of the intravascular volume increases the glomerular filtration rate (GFR) and oxygen delivery and dilutes myoglobin and other renal tubular toxins.

• Immediately obtain intravenous access with a large-bore catheter.

• Administer isotonic crystalloid 500 mL/h and then titrate to maintain a urine output of 200-300 mL/h.

• Because injured myocytes can sequester large volumes of extracellular fluid, crystalloid requirements may be surprisingly large.

Emergency Department Care: Assess ABCs and support as needed. Treat any underlying conditions, such as trauma, infection, or toxins. General recommendations for the treatment of rhabdomyolysis include fluid resuscitation and prevention of end-organ complications.

• Patients with CK elevation in excess of 2-3 times the reference range, appropriate clinical history, and risk factors should be suspected of having rhabdomyolysis. Administer isotonic crystalloid 500 mL/h and titrate to maintain a urine output of 200-300 mL/h. (Consider central venous pressures or Swan-Ganz catheterization in patients with cardiac or renal disease. These invasive studies can assist in the assessment of the intravascular volume.) Repeat CK assay every 6-12 hours in order to determine peak CK level.

• Acute renal failure develops in 30-40% of patients with rhabdomyolysis. Suggested mechanisms include precipitation of myoglobin and uric acid crystals within renal tubules, decreased glomerular perfusion, and the nephrotoxic effect of ferrihemate (formed upon dissociation of myoglobin in the acidic environment of the renal parenchyma). In a 1988 review, Ward suggested that predictors for the development of renal failure include peak CK level more than 6000 IU/L, dehydration (hematocrit >50, serum sodium level >150 mEq/L, orthostasis, pulmonary wedge pressure <5 mm Hg, urinary fractional excretion of sodium <1%), sepsis, hyperkalemia or hyperphosphatemia on admission, and the presence of hypoalbuminemia. Acute renal failure has occasionally developed in severely dehydrated patients with peak CK level as low as 2000 IU/L. To prevent renal failure, many authorities advocate urine alkalinization, mannitol, and loop diuretics.

• Urinary alkalinization to prevent the development of acute renal failure in patients with rhabdomyolysis has been supported by animal studies and retrospective human studies, although prospective randomized human studies are lacking.

• Urinary alkalinization is recommended for patients with rhabdomyolysis and CK levels in excess of 6000 IU/L. Alkalinization should be considered earlier in patients with acidemia, dehydration, or underlying renal disease. A suggested regimen is 0.5 isotonic sodium chloride solution with one ampule of sodium bicarbonate administered at 100 mL/h and titrated to a urine pH higher than 7.

• After establishing an adequate intravascular volume, mannitol may be administered to enhance renal perfusion.

• Loop diuretics may be used to enhance urinary output in oliguric patients, despite adequate intravascular volume.

• Treatment of hyperkalemia consists of intravenous sodium bicarbonate, glucose, and insulin; oral or rectal sodium polystyrene sulfonate (Kayexalate); and hemodialysis. Administer intravenous calcium chloride for patients who are hemodynamically compromised and hyperkalemic.

• Hypocalcemia is noted early in the course of rhabdomyolysis and generally is not of clinical significance. Calcium supplementation is not recommended.

• Compartment syndrome requires immediate orthopedic consultation for fasciotomy.

• DIC should be treated with fresh frozen plasma, cryoprecipitate, and platelet transfusions.

• Hyperuricemia and hyperphosphatemia rarely are of clinical significance and rarely require treatment.

Consultations:

• Nephrologist: Indications for hemodialysis include hyperkalemia that is persistent despite therapy, severe acid-base disturbances, refractory pulmonary edema, and progressive renal failure.

• Orthopedist: Consult an orthopedist in cases of suspected compartment syndrome.

MEDICATION

Section 7 of 11

Medical therapy focuses on restoring adequate intravascular volume using isotonic crystalloid. Adjunctive measures that may decrease the incidence of acute myoglobinuric renal failure include urinary alkalinization and osmotic and loop diuresis.

Drug Category: Alkalinizing agents -- Sodium bicarbonate is administered IV to alkalinize urine in patients with rhabdomyolysis. This may prevent toxicity caused by the presence of myoglobin in acidic urine and crystallization of uric acid.

Drug Name	Sodium bicarbonate (Neut) -- Useful in alkalization of urine to prevent acute myoglobinuric renal failure. Titrate dose to increase pH to >7.
Adult Dose	1 ampule (44 mEq) of sodium bicarbonate is added to 1 L of 0.45 NS and infused at 100 mL/h IV
Pediatric Dose	1.9 mEq/kg IV q1-2h prn
Contraindications	Documented hypersensitivity; alkalosis; hypernatremia; hypocalcemia; severe pulmonary edema; unknown abdominal pain
Interactions	Urinary alkalinization, induced by increased sodium bicarbonate concentrations, may cause decreased levels of lithium, tetracyclines, chlorpropamide, methotrexate, and salicylates; increases levels of amphetamines pseudoephedrine, flecainide, anorexiants, mecamylamine, ephedrine, quinidine, and quinine
Pregnancy	C - Safety for use during pregnancy has not been established.
Precautions	Only use to treat documented metabolic acidosis and hyperkalemia-induced cardiac arrest; can cause alkalosis, decreased plasma potassium, hypocalcemia, and hypernatremia; caution in electrolyte imbalances, such as in patients with CHF, cirrhosis, edema, corticosteroid use, or renal failure; when administering, avoid extravasation because can cause tissue necrosis

Drug Category: Osmotic diuretics -- These agents increase osmolarity of glomerular filtrate and induce diuresis. They hinder tubular reabsorption of water, causing sodium and chloride excretion to increase.

Drug Name	Mannitol (Osmitrol) -- Alternative diuretic used when urine output is inadequate despite aggressive fluid therapy. Initially assess for adequate renal function in adults by administering a test dose of 200 mg/kg IV over 3-5 min. Should produce a urine flow of at least 30-50 mL/h over 2-3 h. In children, assess for adequate renal function by administering a test dose of 200 mg/kg IV over 3-5 min. It should produce a urine flow of at least 1 mL/h over 1-3 h.
Adult Dose	1.5-2 g/kg IV as 20% solution (7.5-10 mL/kg) or as 15% solution (10-13 mL/kg) over a period as short as 30 min
Pediatric Dose	0.5-1 g/kg IV initial; followed by 0.25-0.5 g/kg IV q4-6h maintenance dose
Contraindications	Documented hypersensitivity; anuria; severe pulmonary congestion; progressive renal damage; severe dehydration; active intracranial bleeding; progressive heart failure
Interactions	None reported
Pregnancy	C - Safety for use during pregnancy has not been established.
Precautions	Carefully evaluate cardiovascular status before rapid administration of mannitol because a sudden increase in extracellular fluid may lead to fulminating CHF; avoid pseudoagglutination, when blood given simultaneously, add at least 20 mEq of sodium chloride to each liter of mannitol solution; do not give electrolyte-free mannitol solutions with blood

Drug Category: Loop diuretics -- These agents elicit a loss of free water, increasing diuresis.

Drug Name	Furosemide (Lasix) -- Increases water excretion by interfering with the chloride-binding cotransport system, resulting in inhibition of sodium and chloride reabsorption in the ascending loop of Henle and distal renal tubule. Individualize doses. Depending on response, administer at increments of 20-40 mg q6-8h until desired diuresis occurs. When treating infants, titrate with 1-mg/kg/dose increments until a satisfactory effect is achieved.
Adult Dose	20-40 mg IV q2h prn to maintain urine output; may increase dose by 20 mg q2h prn to desired response
Pediatric Dose	1-2 mg/kg IV q6h; titrate to desired urine output; not to exceed 6 mg/kg/d
Contraindications	Documented hypersensitivity; hepatic coma; anuria; state of severe electrolyte depletion
Interactions	Metformin decreases concentrations; interferes with hypoglycemic effect of antidiabetic agents and antagonizes muscle relaxing effect of tubocurarine; auditory toxicity appears to be increased with coadministration of aminoglycosides and furosemide; hearing loss of varying degrees may occur; anticoagulant activity of warfarin may be enhanced when taken concurrently with this medication; increased plasma lithium levels and toxicity are possible when taken concurrently with this medication
Pregnancy	C - Safety for use during pregnancy has not been established.
Precautions	Perform frequent serum electrolyte, carbon dioxide, glucose, creatinine, uric acid, calcium, and BUN determinations during first few months of therapy and periodically thereafter

FOLLOW-UP

Section 8 of 11

Further Inpatient Care:

• Admit patients with rhabdomyolysis for continued volume support and urinary alkalinization. Obtain serial CK measurements to verify that values have peaked and are returning to reference range.

• Serial physical examinations and laboratory studies are indicated to monitor for compartment syndrome, hyperkalemia, acute oliguric or nonoliguric renal failure, and DIC.

• In patients with no apparent precipitating factors for rhabdomyolysis, consider inherited disorders of carbohydrate or lipid metabolism and myopathies.

Transfer:

• Patients may be transferred to another facility after establishing intravenous access and addressing life- and limb-threatening conditions. Follow guidelines of the Consolidated Omnibus Budget Reconciliation Act (COBRA) and the Emergency Medical Treatment and Labor Act (EMTALA).

Complications:

• Death from hyperkalemia or renal failure

• Compartment syndrome

• DIC

• Hepatic insufficiency

• Acute renal failure

Prognosis:

• The prognosis is dependent upon the underlying etiology and any existing comorbidities.

Patient Education:

• Advise patients with rhabdomyolysis caused by hyperthermia and/or inordinate exertion to exercise in moderation with careful attention to hydration and external methods of cooling.

• Advise patients with rhabdomyolysis related to ethanol, recreational drugs, or prescription medications to discontinue use of the offending agent and refer them to a rehabilitation program.

MISCELLANEOUS

Section 9 of 11

Medical/Legal Pitfalls:

• Failure to recognize rhabdomyolysis on initial presentation

• Failure to institute early and aggressive volume replacement

• Insufficient monitoring for serious complications, such as compartment syndrome and severe hyperkalemia

TEST QUESTIONS

Section 10 of 11

CME Question 1: When considering the possibility of rhabdomyolysis, when can the diagnosis be excluded safely?

A: If a careful history reveals no risk factors and the patient denies muscle soreness and weakness
B: If the physical examination findings are entirely within normal limits
C: If a urine dipstick for blood (orthotoluidine test) has negative results
D: If the serum creatine kinase level is within reference range
E: If the serum potassium, blood urea nitrogen, creatinine, calcium, and phosphorus levels are all within reference range

The correct answer is D: In Gabow’s series, 3% of patients with rhabdomyolysis had no discernible risk factor, and only 50% complained of muscle pain on admission. Objective findings of muscular edema are noted in only 5% of cases. A urine dipstick for blood (orthotoluidine test) with positive results, coupled with absence of microhematuria, suggests the presence of myoglobinuria and rhabdomyolysis; however, this test is insensitive, being positive only in approximately one half of patients with rhabdomyolysis.

CME Question 2: Which of the following aspects regarding treatment of rhabdomyolysis is accurate?

A: The single most important aspect of therapy is early institution of intravenous crystalloid therapy.
B: The single most important aspect of therapy is alkalinization of the urine via intravenous bicarbonate therapy and maintenance of urine output using osmotic and loop diuretics in combination.
C: Serum calcium, phosphorus, and uric acid levels should be maintained within the reference range using calcium supplements, phosphate binders, and allopurinol.
D: The physician must be careful not to induce a net positive fluid balance to avoid precipitating muscle compartment syndromes.
E: Severe hyperkalemia cannot be treated in the usual fashion because calcium supplements are contraindicated and injured myocytes do not respond to administration of bicarbonate or insulin/glucose.

The correct answer is A: Retrospective human studies suggest that early aggressive crystalloid therapy is critical in preventing the complications of rhabdomyolysis. Adequate volume replacement often produces a positive fluid balance because of sequestration of extracellular fluid within injured myocytes. The use of serum bicarbonate, osmotic agents, and loop diuretics is of theoretical benefit, but definitive benefit has not been established in human subjects. Severe hyperkalemia is treated in the standard fashion with calcium chloride, intravenous bicarbonate, insulin/glucose, and Kayexalate resin.

Pearl Question 1 (T/F): The most common complication of rhabdomyolysis is acute tubular necrosis.

The correct answer is True: Acute tubular necrosis is the most common complication of rhabdomyolysis. Rhabdomyolysis accounts for an estimated 8-15% of acute renal failure cases in the United States.

Pearl Question 2 (T/F): In acute rhabdomyolysis, the serum creatine kinase level usually peaks and remains at peak levels for 7-10 days before falling.

The correct answer is False: Once it has peaked, the creatine kinase level in uncomplicated rhabdomyolysis usually falls by approximately 40% per day. Failure of the serum creatine kinase level to fall by 40% each day may be a sign of compartment syndrome.

Pearl Question 3 (T/F): Prolonged prothrombin time (PT) and activated partial thromboplastin time (aPTT) in a patient with rhabdomyolysis suggest the development of disseminated intravascular coagulation.

The correct answer is True: Disseminated intravascular coagulation is a well-known complication of rhabdomyolysis and typically is manifested by elevations in PT, aPTT, platelet count, and fibrin split products.

Pearl Question 4 (T/F): The most common infectious cause of rhabdomyolysis is influenza.

The correct answer is True: Influenza is the most common infectious cause of rhabdomyolysis. Viral infectious causes of rhabdomyolysis include influenza types A and B (most common), HIV, coxsackievirus, Ebstein-Barr virus, echovirus, cytomegalovirus, adenovirus, herpes simplex virus, parainfluenza virus, and varicella-zoster virus.

BIBLIOGRAPHY

Section 11 of 11

• Beese MS, Winkler G, Maas R, Bucheler E: [MRI of musculature in myalgia--indications and image findings]. Aktuelle Radiol 1996 May; 6(3): 119-29[Medline].
• Berger RP, Wadowksy RM: Rhabdomyolysis associated with infection by Mycoplasma pneumoniae: a case report. Pediatrics 2000 Feb; 105(2): 433-6[Medline].
• Better OS: The crush syndrome revisited (1940-1990). Nephron 1990; 55(2): 97-103[Medline].
• Better OS, Stein JH: Early management of shock and prophylaxis of acute renal failure in traumatic rhabdomyolysis. N Engl J Med 1990 Mar 22; 322(12): 825-9[Medline].
• Boucree MC: Legionnaire's disease and acute renal failure: a case report and literature review. J Natl Med Assoc 1988 Oct; 80(10): 1065-71[Medline].
• Brumback RA, Feeback DL, Leech RW: Rhabdomyolysis in childhood. A primer on normal muscle function and selected metabolic myopathies characterized by disordered energy production. Pediatr Clin North Am 1992 Aug; 39(4): 821-58[Medline].
• Chariot P, Ruet E, Authier FJ, et al: Acute rhabdomyolysis in patients infected by human immunodeficiency virus. Neurology 1994 Sep; 44(9): 1692-6[Medline].
• Gabow PA, Kaehny WD, Kelleher SP: The spectrum of rhabdomyolysis. Medicine (Baltimore) 1982 May; 61(3): 141-52[Medline].
• Jolly BT, Talbot-Stern J: Rhabdomyolysis secondary to keyboard overuse: occupational hazard of the computer age. Am J Emerg Med 1995 Nov; 13(6): 644-6[Medline].
• Lappalainen H, Tiula E, Uotila L: Elimination kinetics of myoglobin and creatine kinase in rhabdomyolysis: implications for follow-up. Crit Care Med 2002 Oct; 30(10): 2212-5[Medline].
• Malinoski DJ, Slater MS, Mullins RJ: Crush injury and rhabdomyolysis. Crit Care Clin 2004 Jan; 20(1): 171-92[Medline].
• Mannix R, Tan ML, Wright R, Baskin M: Acute pediatric rhabdomyolysis: causes and rates of renal failure. Pediatrics 2006 Nov; 118(5): 2119-25[Medline].
• Putterman C, Levy L, Rubinger D: Transient exercise-induced water intoxication and rhabdomyolysis. Am J Kidney Dis 1993 Feb; 21(2): 206-9[Medline].
• Sinert R, Kohl L, Rainone T, Scalea T: Exercise-induced rhabdomyolysis. Ann Emerg Med 1994 Jun; 23(6): 1301-6[Medline].
• Singh U, Scheld WM: Infectious etiologies of rhabdomyolysis: three case reports and review. Clin Infect Dis 1996 Apr; 22(4): 642-9[Medline].
• Visweswaran P, Guntupalli J: Rhabdomyolysis. Crit Care Clin 1999 Apr; 15(2): 415-28, ix-x[Medline].
• Ward MM: Factors predictive of acute renal failure in rhabdomyolysis. Arch Intern Med 1988 Jul; 148(7): 1553-7[Medline].
• Will MJ, Hecker RB, Wathen PI: Primary varicella-zoster-induced rhabdomyolysis. South Med J 1996 Sep; 89(9): 915-20[Medline].
• Wrenn KD, Oschner I: Rhabdomyolysis induced by a caffeine overdose. Ann Emerg Med 1989 Jan; 18(1): 94-7[Medline].
• Zager RA: Rhabdomyolysis and myohemoglobinuric acute renal failure. Kidney Int 1996 Feb; 49(2): 314-26[Medline].

eMedicine Journals > Emergency Medicine > Trauma And Orthopedics > Rhabdomyolysis

Please email us with any comments you have on our new chapter format.

Author Information | Introduction | Clinical | Differentials | Workup | Treatment | Medication | Follow-up | Miscellaneous | Test Questions | Bibliography